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1. Biochemical structure and molecular activity
of meldonium
Meldonium (commercial name Mildronate) was originally
synthesized in the mid-1970s at the Institute of Organic Syn-
thesis of the Latvian Soviet Socialist Republic Academy of
Sciences. The chemical structure of this compound (3-(2,2,2-
trimethylhydraziniumyl)propionate) is similar to that of 2 bio-
logically important betaines, γ-butyrobetaine and carnitine.1
Compared to γ-butyrobetaine, in meldonium, an amino group
has replaced the CH2 at the C-4 position (Fig. 1). The primary
mechanism of action of meldonium entails a competitive inhi-
bition of γ-butyrobetaine hydroxylase, a pivotal enzyme in the
metabolic pathway of carnitine biosynthesis (Fig. 1). The com-
pound also binds to, and hence inhibits, the enzyme carnitine
acetyltransferase, although this latter effect appears weaker
than that on γ-butyrobetaine hydroxylase. According to this
biological pathway, meldonium is thought to reduce the endog-
enous synthesis and biological activity of carnitine. Carnitine
plays a pivotal role in transportation of activated long-chain
fatty acids and other products of peroxisomal β-oxidation
(especially acetyl-CoA) to the mitochondria, but also modu-
lates the acyl-CoA/CoA ratio, optimizes energy storage, and
reduces the toxic effects of poorly metabolized acyl groups.2
The metabolism of this compound culminates with the genera-
tion of trimethylamine-N-oxide, which is involved in the patho-
genesis of both atherosclerosis and heart failure.2 Recently,
meldonium was also found to exert an effective inhibition of
Organic Cation/Carnitine Transporter 2, a widely expressed
enzyme in mammalian tissues which functions as a sodium-
coupled carnitine transporter.3
Therefore, since meldonium ultimately decreases carnitine
availability in the cell, the leading metabolic consequences
include a shift of fatty acid metabolism from mitochondria to
peroxisomes, a reduced formation of long-chain acylcarnitines,
and a protection of mitochondrial injury due to excessive fatty
acid oxidation and overload of fatty acid end-products (Fig. 1).3
2. Meldonium improves post-ischaemic recovery
Due to the important regulatory activity on fatty acid
metabolism, meldonium is currently used as a cardioprotective
drug, especially for enhancing preconditioning-like adaptive
responses. The putative effects that have been ascribed to
meldonium in animal studies include prevention of atheroscle-
rosis progression, reduction of infarct size following myocardial
ischaemia, attenuation of ventricular remodelling, protection
against left ventricular dysfunction, improvement of functional
heart parameters, and decrease of both incidence and severity of
cardiac arrhythmias.3 Notably, this metabolic modulator is not
currently approved for clinical use by the U.S. Food and Drug
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Fig. 1. Metabolism of meldonium and carnitine. The administration of
meldonium competitively inhibits the enzyme γ-butyrobetaine hydroxylase
(BBD), which converts γ-butyrobetaine in carnitine, but also reduces carnitine
adsorption by inhibiting the sodium-coupled carnitine transporter Organic
Cation/Carnitine Transporter 2 (OCTN2). The final effect is a decreased
transportation and metabolism of long-chain fatty acids and acetyl-CoA in the
mitochondria and, consequently, a decreased risk of mitochondrial injury from
fatty acid oxidation, increased generation of long-chain acylcarnitines and
enhanced production of fatty acid end-products.
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Administration and in many countries of the European Union,
and can only be prescribed in some Eastern European Counties
such as Russia, Ukraine, Moldova, Belarus, Azerbaijan, and
Armenia, or else it can be ordered through many virtual phar-
macies available on the Web.
3. Clinical trials using meldonium show promising results
in patients with heart failure
In addition to many beneficial effects of meldonium demon-
strated in animal models,3 a limited number of human studies
also have shown promising results. Vasiuk et al.4 studied 55
patients with chronic heart failure after myocardial infarction
and with a left ventricular ejection fraction of less than 40%.
The patients were randomized to receive basic therapy alone,
basic therapy plus trimethasidine, and basic therapy plus
meldonium. A significant attenuation of glucose hypermetabo-
lism in the ischaemic segment along with a lower functional
class of chronic heart failure, and a prolonged distance for a
6-min walk test was recorded in both groups treated with
trimethasidine or meldonium. Zhu et al.5 carried out a random-
ized, double-blind, multicenter clinical study including 227
patients with acute cerebral infarction, 113 of whom received
500 mg/day meldonium, whereas the remaining 114 received
cinepazide. Similar improvements of functional scores (e.g.,
Modified Rankin Scale (mRS), National Institutes of Health
Stroke Scale score and Barthel Index) were observed between
groups after 3 months of therapy, which led the authors to
conclude that meldonium may be as effective as cinepazide for
treating acute cerebral infarction. Statsenko et al.6 studied 60
patients with myocardial infarction and symptoms of Func-
tional Class II–III heart failure, who were randomized to
receive standard therapy or standard therapy plus meldonium
1000 mg/day. After 10–14 days of therapy, patients receiving
meldonium displayed major clinical improvements and more
favorable changes in cardiac structural and functional param-
eters than those receiving only standard therapy. Smirnova
et al.7 studied 56 patients with cardiovascular disease, who were
randomized to receive basic therapy or basic therapy plus
500 mg/day meldonium. A marked decrease of systolic blood
pressure, a reduction of heart rate during heat, along with a
better quality of life score (e.g., visual analogue scale) and
improved adaptative responses were noticed in the group of
patients treated with meldonium.
Despite the fact that meldonium is thought to be relatively
safe and the number of side effects was found to be lower than
15% in clinical studies,5 some potential complications have
been reported, including 1 case of sudden death after peripheral
embolism and ischaemic stroke (reported by a physician from
the Russian Federation in a 69-year-old patient using multiple
drugs other than meldonium), 1 case of multi-organ failure
(reported by a health professional from Ukraine in a 74-year-
old patient), along with additional cases of patients with diar-
rhoea, anaemia, fatigue, and serum bilirubin increase.8
4. Meldonium may improve endurance performance
Due to its putative anti-ischaemic effect, there are many
attractive incentives that may persuade both professional and
elite athletes to misuse meldonium in sports. Such incentives
include an improved peroxisomal utilization of fatty acids by
the exercising muscles, a decreased production of lactate after
exercise, an improved storage and utilization of glycogen, as
well as the prevention of oxidative stress after intense muscular
workload. These effects predictably translate into enhanced
aerobic endurance and physical work potential, improved func-
tional heart activity, ameliorated recovery after maximal and
sub-maximal loads of exercise, and enhanced activation of
central nervous system functions (Table 1).9
5. Meldonium is misused by athletes
According to its manifold biological functions, meldonium
has been included in the list of prohibited substances since 2016
by the World Anti-Doping Organization (WADA).10 An assay
for urine assessment of this compound has also been recently
published,9 based on the use of hydrophilic interaction liquid
chromatography-high resolution/high accuracy mass spectrom-
etry. The method showed adequate lower limit of detection,
excellent specificity and robustness, optimal linearity and low
imprecision, which made it suitable to be included in the
already long list of anti-doping tests currently performed by
many national and international organizations, including
WADA.
Not surprisingly, the number of positive anti-doping tests for
this banned compound has exponentially increased over the
past few months, involving many top-class athletes (over 170 as
of April 14, 2016).11 This evidence reflects data published in a
recent study, showing that 182 positive meldonium findings
were detected out of 8320 random doping control urine samples
covering different sports (i.e., 2.2%), with drug concentrations
comprised between 0.1 and 1428 μg/mL.9 Interestingly, posi-
tive samples were found in a wide range of sport disciplines,
thus suggesting that the misuse of this metabolic modulator
may not be limited to certain categories of athletes.
6. Concluding remarks
In the long history of doping in sports, competitive athletes
have searched for illegal advantages by misusing various modu-
lators of aerobic performance, such as erythropoiesis stimulat-
ing substances (e.g., erythropoietin and analogues), blood
transfusions, and also metabolic modulators, such as hypoxia-
inducible factor 1 (HIF-1) and cobalt chloride.12 Meldonium
is currently claimed to be a relatively safe agent in patients
Table 1
Meldonium in sports.
Putative ergogenic effects of meldonium
1. Improved peroxisomal utilization of fatty acids
2. Decreased production of lactic acid
3. Improved storage and utilization of glycogen
4. Prevention of oxidative stress
5. Enhanced endurance aerobic and physical work capabilities
6. Improved functional parameters of heart activity
7. Ameliorated recovery after maximal and sub-maximal exercise
8. Enhanced activation of central nervous system functions
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needing anti-ischaemic therapy, but there is no compelling
evidence that it may be effective in improving athletic
performance, nor that its administration may be safe in healthy
subjects. Therefore, action should be taken to prevent the
misuse of meldonium and to identify athletes who may
jeopardize their health by attempting to artificially enhance
performance.
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